Moderna announced it has swung to a profit as Covid-19 vaccine demand stabilizes. The biopharmaceutical company lifted its full-year revenue outlook, now expecting growth between 15% and 25%, up from a previous forecast of up to 10% growth. This upward revision reflects improved market conditions and sustained demand for its vaccine portfolio.
The company's financial turnaround comes as the pandemic transition phase reshapes global vaccination strategies. Moderna's leadership expressed confidence in maintaining momentum through new product developments and geographic expansion. The outlook shift signals a significant recovery from earlier pandemic-related volatility.
Analysts view the guidance boost as a positive indicator for the broader biotech sector navigating post-pandemic dynamics. The company's strategic pivot toward diversified revenue streams appears to be yielding results amid shifting public health landscapes.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing